The Gemini Brief – Investment Deep Dives

McKesson Corporation (MCK): An In-Depth Investment Analysis

All investment deep dives on this site were written by Gemini and Claude LLMs with light human editing. Nothing on this site constitutes investment advice. All materials are for informational purposes only.

The Gemini Brief - Investment Deep Dives
The Gemini Brief – Investment Deep Dives
McKesson Corporation (MCK): An In-Depth Investment Analysis
Loading
/

Executive Summary

McKesson Corporation stands as a foundational pillar of the North American healthcare ecosystem, operating as the largest pharmaceutical distributor in a highly concentrated oligopoly.1 The company’s core business is defined by immense scale, operational precision, and stable, recurring revenue streams, which collectively generate substantial and predictable cash flow. For the fiscal year ended March 31, 2025, McKesson reported consolidated revenues of $359.1 billion, a 16% year-over-year increase, and generated $5.2 billion in free cash flow, underscoring its financial strength and critical role in the supply chain.4

The central investment thesis for McKesson revolves around a deliberate and multifaceted strategic transformation. The company is leveraging the financial stability of its mature, low-margin distribution business to fund a pivot into higher-growth, higher-margin healthcare services, with a distinct focus on the oncology and biopharmaceutical sectors.4 This strategic shift is being crystallized through a new organizational structure, effective in the second quarter of fiscal 2026, and the planned separation of its Medical-Surgical Solutions segment. These actions are designed to enhance strategic focus, improve transparency for investors, and ultimately unlock shareholder value by allowing the market to more accurately price its distinct business lines.4

Key opportunities for the company are centered on its ability to expand its leadership position in the high-value specialty and oncology markets, capitalize on its scale and technological investments to drive further operational efficiencies, and continue its disciplined approach to capital allocation that has consistently returned significant value to shareholders.

However, this strategic evolution is set against a backdrop of significant industry-wide challenges. Principal risks include persistent margin compression from generic drug pricing deflation, intensifying regulatory and antitrust scrutiny as the company integrates vertically into provider services, and the inherent execution risk associated with a complex strategic pivot and the separation of a major business segment. McKesson is thus at a strategic inflection point, tasked with balancing the formidable stability of its legacy operations with a decisive push into more dynamic and profitable healthcare verticals. The investment merits hinge on management’s ability to successfully navigate this transformation while mitigating the formidable headwinds shaping the modern healthcare landscape.

Company Analysis: The Scale and Strategy of a Healthcare Linchpin

Business Model and Value Chain Position

McKesson Corporation functions as an indispensable intermediary in the complex U.S. healthcare supply chain. Its fundamental business model involves sourcing pharmaceuticals, medical supplies, and healthcare products from hundreds of manufacturers and distributing them to a vast network of over 285,000 customers.8 These customers include retail pharmacies (both national chains and independents), hospitals, health systems, physician offices, and long-term care facilities. The company’s immense scale—delivering over 40 million pharmaceutical and medical supply products annually—and operational excellence, highlighted by a 99% pharmaceutical order accuracy rate in North America, are paramount to its success.8

The core distribution business is characterized by extremely high revenue volume and razor-thin operating margins. This economic reality makes logistical efficiency, sophisticated inventory management, and purchasing power the primary drivers of profitability. A significant portion of McKesson’s revenue is recurring in nature, underpinned by long-term, high-volume contracts with major customers like national pharmacy chains and large hospital systems. These multi-year agreements provide a stable and predictable revenue base, which is a key characteristic of the business model.

Analysis of Reportable Segments (Fiscal Year 2025)

Prior to its announced restructuring, McKesson operated under four reportable segments, each serving a distinct part of the healthcare market. The performance of these segments in fiscal year 2025 provides the baseline for understanding the company’s strategic realignment.

  • U.S. Pharmaceutical: This is the company’s largest and most critical segment, serving as the primary engine for revenue and cash flow. It distributes a full range of branded, generic, specialty, and over-the-counter pharmaceutical drugs. For fiscal 2025, the segment generated revenues of $327.7 billion, an 18% increase from the prior year. This growth was driven by higher prescription volumes from retail national account customers and robust expansion in the distribution of higher-value specialty products, particularly in oncology.4 Adjusted Segment Operating Profit grew 12% to $3.7 billion.4
  • Prescription Technology Solutions (RxTS): This segment represents a key part of McKesson’s strategic push into higher-margin, technology-enabled services. RxTS connects biopharma companies, pharmacies, and patients to address challenges related to medication access, affordability, and adherence. In fiscal 2025, RxTS revenues grew 13% to $5.0 billion, with Adjusted Segment Operating Profit rising 15% to $1.0 billion, driven by strong demand for its access and affordability solutions.4
  • Medical-Surgical Solutions: This segment focuses on distributing a wide array of medical-surgical supplies and equipment to non-hospital settings, such as physician offices, surgery centers, and long-term care facilities. In fiscal 2025, revenues were essentially flat year-over-year at $11.4 billion, while Adjusted Segment Operating Profit was also flat at $1.0 billion, as operational efficiencies were offset by shifts in product demand and customer mix.4 In May 2025, McKesson announced its intention to separate this segment into an independent, publicly traded company to sharpen the strategic focus of both entities.4
  • International: This segment has been contracting as part of a deliberate strategy to exit the European market and concentrate on North American operations. It primarily consists of distribution and retail pharmacy operations in Canada and Norway. The sale of its Canadian retail disposal group, which included the Rexall and Well.ca businesses, was completed on December 30, 2024, further streamlining the segment’s focus.5

Strategic Realignment: The New Organizational Structure

On September 18, 2025, McKesson announced a significant change to its organizational and reporting structure, effective in the second quarter of fiscal 2026.7 This realignment is a direct reflection of the company’s evolving strategy to accelerate growth in its most profitable and promising businesses.6 The new structure is composed of:

  • North American Pharmaceutical: The foundational U.S. and Canadian pharmaceutical distribution and related services businesses.
  • Oncology & Multispecialty: This newly highlighted segment combines McKesson’s deep capabilities in specialty drug distribution with its provider-facing services, most notably The U.S. Oncology Network. This network is a market leader, supporting approximately 2,600 community-based providers across 600 sites.7
  • Prescription Technology Solutions: This segment remains focused on its mission to connect the healthcare ecosystem and improve patient access through technology and biopharma services.
  • Medical-Surgical Solutions: This segment will be managed with the intent to separate it into an independent company.7

This restructuring is far more than an administrative change; it is a clear signal to investors about where management believes future value resides. The pharmaceutical distribution industry has historically been valued on very low multiples (such as a price-to-sales ratio around 0.2x) due to its low-margin profile.11 In contrast, high-growth, high-margin businesses like oncology services and biopharma technology platforms typically command significantly higher valuation multiples from the market.

By creating a distinct “Oncology & Multispecialty” segment and issuing specific, ambitious long-term growth targets for it—13% to 16% adjusted operating profit growth—management is explicitly inviting analysts and investors to adopt a “sum-of-the-parts” valuation framework.6 This approach allows for a separate, higher valuation of the growth-oriented segments, which could unlock shareholder value currently obscured within the consolidated, low-margin perception of the overall company. The planned separation of the slower-growing Medical-Surgical business is the culminating step in this strategy to purify the business mix and focus capital on the most promising opportunities.

Segment Performance (Fiscal Years ended March 31)
(in millions)FY 2023FY 2024FY 2025FY 2023FY 2024FY 2025
RevenuesAdj. Operating Profit
U.S. Pharmaceutical$244,792$278,252$327,700$3,040$3,313$3,700
Prescription Technology Solutions$4,101$4,420$5,000$678$870$1,000
Medical-Surgical Solutions$11,114$11,288$11,400$1,032$1,000$1,000
International$16,704$14,991$14,951$385$378$428
Total$276,711$308,951$359,051$4,524$5,011$5,516
Source: Company 10-K filings and FY2025 Earnings Release.4 Totals may not sum due to intersegment eliminations and rounding.

Industry Dynamics and Competitive Positioning

Market Structure: A Stable Oligopoly

The U.S. pharmaceutical distribution industry is a textbook example of a mature oligopoly. The market is dominated by the “Big Three”—McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health—which collectively control an estimated 95% to 98% of the wholesale distribution market.1 McKesson stands as the market leader, commanding an approximate 37% share, followed by Cardinal Health with about 28%.3

The barriers to entry in this industry are exceptionally high, effectively precluding new, large-scale competition. These barriers are built on:

  1. Massive Scale: The capital investment required to build a national network of distribution centers with the necessary technology and inventory is prohibitive.
  2. Complex Logistics: The industry demands sophisticated logistics, IT infrastructure, and cold-chain capabilities to manage millions of SKUs and ensure timely, accurate delivery.
  3. Customer Relationships: The “Big Three” have deeply entrenched, long-standing relationships with major pharmacy chains, hospital systems, and government agencies, which are difficult for a new entrant to displace.
  4. Regulatory Hurdles: Navigating the complex web of federal and state regulations, including the Drug Enforcement Administration’s (DEA) stringent requirements for controlled substances, requires significant expertise and investment.

The primary competitive moat for these distributors stems from high customer switching costs.1 These costs are not just financial but deeply operational. Customers are integrated into the distributors’ ordering and inventory management systems (e.g., McKesson Connect 14), and their supply chains are optimized around the distributors’ networks. Furthermore, joint ventures for generic drug sourcing, such as McKesson’s ClarusONE partnership, create a powerful incentive for customers to remain within the ecosystem to maximize purchasing power.15

Peer Comparison: McKesson vs. Cencora vs. Cardinal Health

While functionally similar, the “Big Three” exhibit subtle differences in scale and strategic focus. McKesson is the largest by revenue. All three are aggressively pursuing a similar strategy of vertical integration into higher-margin specialty services to offset the structural margin pressures in their core distribution businesses.1 This has led to a competitive push into areas like specialty pharmacy, physician practice management (particularly in oncology), and biopharma manufacturer services. Recent acquisitions of physician networks by both McKesson and Cardinal Health have drawn the attention of the Federal Trade Commission (FTC), which is scrutinizing these moves for potential anti-competitive effects.2 Profitability profiles are broadly similar, with razor-thin operating margins (typically in the 1-2% range) on high revenue volumes.

Key Industry Growth Drivers

While the overall market for pharmaceuticals grows at a steady, low-single-digit rate, driven by macro trends like an aging population and rising prescription utilization, several specific factors are driving more dynamic growth 1:

  • Specialty Pharmaceuticals and Biologics: This is the most significant growth driver for the industry. Specialty drugs, which include complex biologics, cell and gene therapies, and treatments for rare diseases, now account for over half of all drug spending despite representing only a small fraction of total volume.17 These products are more expensive and often require specialized handling, such as temperature-controlled cold-chain logistics, which provides distributors with higher-margin service opportunities.1
  • GLP-1 Medications: The recent explosion in demand for GLP-1 agonists for diabetes and weight loss has provided a substantial revenue tailwind for distributors. While these are high-cost branded drugs and thus carry lower margins than generics, the sheer volume has been a major contributor to top-line growth, accounting for an estimated one-fourth of the “Big Three’s” revenue growth over the past year.1

Regulatory Environment and Pressures

The highly concentrated nature of the pharmaceutical distribution industry creates a complex and challenging regulatory environment. The stability afforded by the oligopoly structure is a double-edged sword. On one hand, it limits direct price competition among the major players, leading to a rational market. On the other hand, this concentration makes the industry a highly visible and frequent target for regulators and legislators concerned with the high cost of healthcare in the U.S.

This dynamic creates a persistent “headline risk” and regulatory uncertainty that can weigh on the valuation multiples of all three major distributors. The primary risk is not that a new competitor will emerge to disrupt the market, but rather that the government will unilaterally change the rules of the game for the existing players. This has been demonstrated through drug pricing legislation like the Inflation Reduction Act (IRA), which alters Medicare reimbursement and could indirectly affect the economics of the entire supply chain, and through the coordinated, multi-state opioid litigation that held the distributors collectively accountable.5 The industry’s structure effectively concentrates this regulatory risk.

Financial Performance and Capital Allocation Analysis

A five-year review of McKesson’s financial performance reveals a company with consistent top-line growth, stable (albeit low) margins in its core business, and a strong commitment to returning capital to shareholders. This financial strength has enabled its strategic pivot towards higher-growth areas.

McKesson Corporation: 5-Year Financial Summary
(in millions, for fiscal years ended March 31)FY 2021FY 2022FY 2023FY 2024
Revenues$238,228$263,966$276,711$308,951
Gross Profit$11,514$12,216$12,900$12,852
Operating Income (Loss)($6,799)$2,764$4,583$4,383
Net Income (Loss) Attributable to McKesson($4,539)$1,114$3,560$3,002
Diluted EPS (Loss)($28.26)$7.26$25.03$22.39
Total Debt$14,473$12,300$11,251$11,692
Shareholders’ Equity (Deficit)$175($1,792)($1,490)($1,599)
Cash Flow from Operations$4,542$4,434$5,159$4,314
Free Cash Flow (Calculated)$3,901$3,858$4,416$3,516
Source: Data compiled from Macrotrends and company 10-K filings.4 Total Debt includes both short-term and long-term portions. Free Cash Flow is calculated as Cash Flow from Operations less Capital Expenditures.

Revenue and Profitability Trend Analysis

McKesson’s revenue has demonstrated consistent growth over the past five years, with a notable acceleration in fiscal 2024 (11.7% growth) and fiscal 2025 (16.2% growth).19 This top-line momentum has been fueled by broad market growth, higher volumes from key retail national account customers, and the successful expansion of its higher-priced specialty drug distribution business.4

However, the company’s profitability profile reflects the structural challenges of its industry. Gross profit margins have remained thin and under pressure. In fiscal 2025, for example, gross profit grew by only 4%, significantly lagging the 16% revenue growth, which points to ongoing margin compression.4 This pressure is largely attributable to the deflationary pricing environment for generic drugs and a sales mix shift towards lower-margin specialty and branded pharmaceuticals, including GLP-1s.1

Net income trends require careful interpretation. The significant net loss of $4.54 billion in fiscal 2021 was not an operational failure but the result of the company recording an $8.1 billion pre-tax charge to establish a reserve for its estimated liability in the national opioid litigation.20 In subsequent years, net income has shown a strong recovery and healthy growth, reaching $3.30 billion in fiscal 2025.20 This underlying profitability, combined with an aggressive share repurchase program, has driven strong growth in earnings per share.

Return Metrics and Balance Sheet Considerations

Evaluating McKesson’s return on equity (ROE) is misleading due to a significant accounting artifact on its balance sheet: negative shareholders’ equity. Since fiscal 2022, the company’s total liabilities have exceeded its total assets on an accounting basis, resulting in a negative book value of equity.21 This situation is not a sign of impending insolvency but rather the direct consequence of the company’s capital allocation policy. The combination of substantial capital returns to shareholders (primarily through share buybacks) and the large, one-time charge for the opioid settlement has exceeded the level of retained earnings, eroding the book value of equity into negative territory.

This accounting reality makes price-to-book (P/B) ratios meaningless and renders ROE calculations impossible. Consequently, investors must focus on alternative metrics to assess financial health and efficiency. Return on invested capital (ROIC), which measures profitability relative to the total capital base (both debt and equity), provides a more insightful view of how efficiently management is deploying capital. Similarly, cash-flow-based metrics, such as free cash flow yield, are critical for valuing a business whose worth is derived from its ability to generate cash rather than its accounting book value.

Capital Allocation Strategy

McKesson employs a disciplined and shareholder-friendly capital allocation strategy that balances reinvestment in the business with significant returns of capital to shareholders.

  • Share Repurchases: This is the company’s primary method for returning capital. In fiscal 2025 alone, McKesson repurchased $3.1 billion of its common stock.5 In July 2023, the Board of Directors authorized an additional $6.0 billion for share repurchases, signaling a continued commitment to this strategy.26 These buybacks reduce the share count, providing a direct boost to earnings per share.
  • Dividends: The company has a strong track record of consistent dividend growth. In July 2025, the Board approved a 15% increase in the quarterly dividend to $0.82 per share, marking the ninth consecutive year of increases.27 Despite this growth, the dividend payout ratio remains very low (approximately 8.5% of adjusted earnings 11), indicating that the dividend is extremely well-covered by earnings and has ample room for future growth.
  • Strategic M&A and Divestitures: McKesson actively uses mergers, acquisitions, and divestitures to shape its portfolio. Recent activity has been squarely focused on advancing its strategic priorities. Acquisitions have targeted high-growth areas, such as the purchases of healthcare data platform Compile, Inc. in January 2024, and provider management services companies PRISM Vision and Florida Cancer Specialists in 2025.4 Concurrently, divestitures have been used to streamline the business and exit non-core markets, most notably the multi-year process of exiting its European businesses and the sale of its Canadian retail operations.29

Strategic Initiatives and Growth Trajectory

Pillars of Growth: Oncology and Biopharma Services

McKesson’s long-term growth strategy is predicated on expanding its presence beyond the confines of low-margin distribution into higher-value, more profitable healthcare services. The two central pillars of this strategy are oncology and biopharma services.

The company’s investment in oncology is anchored by The U.S. Oncology Network, a differentiated and market-leading asset that provides a comprehensive suite of services—including practice management, technology solutions, and group purchasing organization (GPO) benefits—to a large network of community-based oncology practices.7 McKesson is actively expanding this platform through acquisitions, such as the announced deal to acquire a controlling interest in Florida Cancer Specialists, which further solidifies its leadership in managing physician practices.4 This vertical integration strategy allows McKesson to capture value across the cancer care continuum, from drug distribution to patient care delivery.

In parallel, the company is scaling its biopharma services platform. Through its Prescription Technology Solutions segment, McKesson offers solutions that help biopharmaceutical manufacturers improve patient access to and affordability of their medications. In the past year, this platform helped patients save over $10 billion on brand and specialty medications and prevented an estimated 12 million prescriptions from being abandoned due to cost.4 These services create a valuable partnership with manufacturers and represent a significant, higher-margin revenue stream.

Technology and Operational Efficiency

In a business where margins are measured in basis points, operational efficiency is not just a goal but a critical competitive advantage. McKesson is making significant investments in technology and automation to fortify this advantage. The company has been integrating advanced automation, including robotics and AI, into its distribution centers.30 These investments serve a dual purpose: they increase the speed and accuracy of picking, packing, and shipping operations, and they help mitigate the impact of labor shortages and wage inflation, which have been persistent headwinds in the post-COVID era.31 By reducing reliance on manual, labor-intensive tasks, McKesson can de-risk its operations and protect its slim margins.

Updated Long-Term Financial Outlook

At its Investor Day in September 2025, McKesson’s management provided an updated and more ambitious long-term financial outlook, reflecting confidence in its strategic direction. The company raised its long-term Adjusted Earnings per Diluted Share growth target to a range of 13% to 16%, up from a prior target of 12% to 14%.6

More revealingly, the company introduced long-term Adjusted Segment Operating Profit growth targets for its newly defined segments:

  • North American Pharmaceutical: 5% to 8%
  • Oncology & Multispecialty: 13% to 16%
  • Prescription Technology Solutions: 10% to 13%

These segment-specific targets are the most crucial piece of forward-looking guidance provided. They quantitatively articulate the company’s growth strategy, clearly signaling that the Oncology & Multispecialty and RxTS segments are expected to grow at a rate more than double that of the core distribution business.6 This provides a tangible framework for investors to model the company’s future earnings mix and to measure management’s success in executing the strategic pivot over the coming years.

Recent Headwinds and Risk Assessment (2022-2024 Focus)

Post-COVID Demand and Supply Chain Normalization

The period from 2022 to 2024 was marked by a normalization of the unique conditions created by the COVID-19 pandemic. The significant, high-margin revenue contribution from the distribution of COVID-19 vaccines and ancillary supply kits, which boosted results in fiscal 2022 and 2023, has largely dissipated.26

Concurrently, the entire pharmaceutical industry has been grappling with severe and prolonged drug shortages. The number of active drug shortages in the U.S. reached a record high of 323 in the first quarter of 2024.35 These shortages are often concentrated in older, low-cost generic sterile injectable drugs and are caused by a combination of factors, including manufacturing quality issues, geopolitical instability, and an over-reliance on a limited number of overseas active pharmaceutical ingredient (API) suppliers.36 While McKesson is a distributor and not a manufacturer, these supply chain disruptions represent a significant operational headwind. They can lead to increased costs associated with sourcing alternative products, damage to customer relationships due to an inability to fulfill orders, and increased complexity in inventory management.

Margin Compression and Generic Drug Pricing

A structural and persistent headwind for pharmaceutical distributors is the deflationary nature of generic drug pricing. While distributors earn higher gross profit margins on generic drugs than on branded products, this profitability is constantly under pressure.1 As a generic drug loses its exclusivity and more manufacturers enter the market, intense price competition ensues, leading to a rapid decline in the drug’s price—a phenomenon often described as a “race to the bottom”.37 This dynamic has, in some cases, made the production of certain essential generic drugs unprofitable, contributing directly to the drug shortage crisis.23 For McKesson, this continuous downward pressure on generic prices acts as a constant drag on overall gross margins.

Opioid Litigation: Quantifying the Aftermath

Between 2022 and 2024, significant progress was made in resolving the massive legal overhang from the opioid crisis. McKesson, along with Cencora and Cardinal Health, became a party to a comprehensive national settlement agreement that resolves the vast majority of opioid-related lawsuits filed by state and local governments. Under the agreement, the three distributors will collectively pay up to $21 billion over an 18-year period, with payments having commenced in 2022.18 McKesson’s portion of this settlement is approximately $7.9 billion.41

The settlement provides crucial clarity on the company’s total financial liability, which is now a known quantity spread over a long duration, making it manageable from a cash flow perspective. However, the impact is not purely financial. The agreement also mandates significant and costly enhancements to the company’s compliance programs and systems for monitoring suspicious orders of controlled substances, representing a lasting operational change stemming from the crisis.18

Macroeconomic Factors: Inflation and Interest Rates

The macroeconomic environment of 2022-2024 introduced further headwinds. As a large employer with an extensive logistics network, McKesson faced pressure from broad-based wage inflation, which increases operating costs. The company’s strategic investments in automation are a direct response to this challenge.31

Furthermore, as a highly working capital-intensive business that must finance vast amounts of inventory and accounts receivable, McKesson is sensitive to changes in interest rates. The period of rising interest rates from 2022 onward increased the cost of borrowing, particularly for short-term financing instruments like commercial paper that the company utilizes.5 Higher financing costs can directly impact the company’s net interest expense and overall profitability.

Key Business Risks

Beyond these recent headwinds, McKesson faces several key ongoing business risks:

  • Customer Concentration: A significant portion of the company’s revenue is derived from a small number of large customers, such as major retail pharmacy chains. The loss or adverse renegotiation of a major contract would have a material impact on financial results.
  • Regulatory and Compliance Risk: This remains the most significant risk category. It includes the threat of further drug pricing legislation, potential antitrust challenges to its vertical integration strategy, and continued stringent oversight from the DEA regarding the distribution of controlled substances.5
  • Technology and Cybersecurity: The company’s operations are critically dependent on its complex IT and logistics systems. A major cybersecurity breach or system failure could cause significant operational disruption and financial damage.5

Valuation Analysis

An analysis of McKesson’s valuation multiples indicates that the market is currently awarding the company a premium relative to its direct peers and its own historical trading ranges. This suggests that investors are pricing in a degree of optimism regarding the company’s strategic direction and financial execution.

Peer Valuation Comparison (as of September 2025)
MetricMcKesson (MCK)Cencora (COR)Cardinal Health (CAH)Peer AverageUS Healthcare Industry Avg.
P/E (TTM)27.8x29.6x23.1x26.8x21.5x
P/E (Forward)18.6x18.2x15.9x17.6xN/A
EV/EBITDA (TTM)17.6x14.1x16.2x16.0xN/A
Price / Sales (TTM)0.23x0.18x0.16x0.19xN/A
Dividend Yield0.47%0.76%1.37%0.87%N/A
Source: Data compiled from multiple sources including Seeking Alpha, Simply Wall St, and multiples.vc.11 TTM = Trailing Twelve Months. Peer Average calculated for MCK, COR, CAH.

Relative Valuation Analysis

As of September 2025, McKesson’s trailing twelve-month (TTM) P/E ratio of approximately 27.8x stands at a premium to its direct competitor Cardinal Health (23.1x) and is roughly in line with Cencora (29.6x).11 It also trades above the broader U.S. Healthcare industry average P/E of around 21.5x.44 An examination of historical data shows that McKesson’s current P/E multiple represents an expansion compared to its own 3-year and 5-year average P/E ratios, which are closer to 22x and 24x, respectively.49

This premium valuation suggests that the market is giving McKesson credit for its strong market leadership, consistent operational execution, shareholder-friendly capital allocation, and the potential of its strategic pivot into higher-growth oncology and biopharma services. The forward P/E multiple of around 18.6x, which is more in line with its peers, indicates that analysts expect strong earnings growth to help justify the current stock price.11

Cash Flow and Yield Perspective

Given the distortions on McKesson’s balance sheet (i.e., negative shareholders’ equity), valuation metrics based on cash flow are particularly important. Based on fiscal 2025 free cash flow of $5.2 billion and a market capitalization of approximately $86.7 billion, McKesson’s free cash flow yield is approximately 6.0%. This represents a solid and tangible return of cash generated by the business relative to its market value.

The company’s dividend yield is currently low, at approximately 0.47%.11 While the dividend itself is growing at a double-digit pace, the low yield indicates that the primary vehicle for capital return is the share repurchase program, not direct income for shareholders.

Factors Driving Multiple Expansion or Contraction

The sustainability of McKesson’s premium valuation will depend on its ability to execute its strategic plan.

  • Potential for Multiple Expansion: If McKesson successfully executes its strategy, particularly in meeting or exceeding the ambitious 13-16% operating profit growth targets for its Oncology & Multispecialty segment, the market may be willing to assign a higher, blended valuation multiple to the entire enterprise. A successful and value-accretive separation of the Medical-Surgical Solutions business could also serve as a positive catalyst.
  • Risk of Multiple Contraction: Conversely, the valuation multiple is at risk of contracting if the company fails to deliver on its growth promises for the new segments. Any significant new regulatory headwinds, such as an antitrust challenge that blocks a strategic acquisition, or a severe and prolonged economic downturn that negatively impacts healthcare utilization and prescription volumes, could also cause the multiple to revert toward its historical averages or peer levels.

Management and Corporate Governance

Management Team and Strategic Vision

McKesson’s senior leadership team, led by Chief Executive Officer Brian Tyler, has articulated and consistently executed a clear strategic vision. This strategy is centered on strengthening the core distribution business while simultaneously reallocating capital and focus toward higher-margin growth platforms in oncology and biopharma services.4 The management team has demonstrated a track record of disciplined execution, successfully achieving a multi-year cost-saving program that delivered over $400 million in savings by the end of fiscal 2021, and navigating the complex divestiture of its European operations.50 Capital allocation has been a hallmark of their tenure, with a balanced approach that has consistently returned substantial capital to shareholders while funding strategic acquisitions.26

Board of Directors and Governance Practices

The company’s corporate governance framework appears robust and aligned with shareholder interests. The Board of Directors is led by an Independent Chair, Donald R. Knauss, ensuring a separation of power from the CEO role.51 The Board has demonstrated a commitment to active refreshment, with recent appointments—such as Lynne Doughtie (former CEO of KPMG U.S.), Dr. Deborah Dunsire (former CEO of H. Lundbeck A/S), and Dr. Julie Gerberding (former Director of the CDC)—bringing deep and highly relevant experience in finance, biopharmaceuticals, and public health policy that directly aligns with McKesson’s strategic priorities and risk environment.10

The company maintains strong governance policies, including a requirement for directors with more than 12 years of tenure to annually offer their resignation and a mandatory retirement age of 75 for non-employee directors.51 These policies promote board refreshment and prevent entrenchment. The Board also conducts a rigorous annual self-evaluation process to assess its effectiveness. Furthermore, the company reports active and ongoing engagement with its shareholders on key topics including corporate strategy, Board composition, executive compensation, and environmental, social, and governance (ESG) matters, indicating a commitment to transparency and accountability.51

Frequently Asked Questions

  • Are earnings at a cyclical high or cyclical low? McKesson’s earnings are not considered cyclical in the traditional sense, as demand for healthcare products is relatively stable regardless of the economic environment. Currently, earnings are on a clear upward trend, driven by consistent market growth, strong performance in specialty pharmaceuticals, and the successful execution of strategic initiatives. The recent performance reflects sustained operational momentum rather than a temporary cyclical peak.  
  • Are earnings driven primarily by the external environment or internal company actions? Earnings are driven by a combination of both. The external environment provides a stable foundation, with macro trends like an aging population and rising prescription drug utilization creating steady demand. However, the primary drivers of  
  • accelerated earnings growth and the core investment thesis are internal company actions. These include a deliberate strategic pivot to higher-margin oncology and biopharma services, disciplined cost management, strategic acquisitions, and a robust capital allocation program focused on share repurchases.  
  • Can this business be easily understood? Yes, at its core, the business model is straightforward and can be easily understood. McKesson acts as a large-scale intermediary, buying pharmaceuticals and medical supplies in massive quantities from manufacturers and distributing them to pharmacies and hospitals for a very small profit margin on each unit sold. The complexity arises from the immense scale of its logistics, the regulatory environment it operates in, and its evolving strategy to add higher-margin technology and provider services on top of its core distribution business.  
  • Can this company be undermined by foreign, low-cost labor? It is highly unlikely. McKesson’s business is primarily a distribution and services network within North America. Its competitive advantages are built on massive physical infrastructure, complex logistics, deep-rooted customer relationships, and navigating a dense U.S. regulatory landscape. These create formidable barriers to entry that cannot be easily replicated or undermined by a foreign competitor relying on low-cost labor.  
  • Do brands matter in the business? Or is this a commodity producer? This is a nuanced question. McKesson is a service provider, not a product producer. In this role, the McKesson brand is critical, signifying reliability, scale, and trust to its customers. However, the core service of distribution is largely a commodity, where competition among the “Big Three” is based on efficiency and scale rather than brand differentiation. The products it distributes are a mix: branded pharmaceuticals, where the manufacturer’s brand is paramount, and generic drugs, which are commodities themselves.  
  • Does the company have assets that are not fully recognized in the balance sheet? Yes. Due to the company’s aggressive share repurchase programs and a large one-time charge for the opioid settlement, it has operated with negative shareholders’ equity, making traditional balance sheet metrics like book value misleading. The company’s most significant assets are intangible and not fully captured on the balance sheet. These include its dominant market position within a stable oligopoly, high customer switching costs, and the powerful network effects of its provider services platforms, particularly The U.S. Oncology Network. While the balance sheet does list over $11.4 billion in goodwill and intangible assets for fiscal 2025, this figure does not fully represent the value of its market leadership and entrenched customer relationships.  
  • Does the company issue large amounts of new shares to insiders? No, the company does the opposite. A key pillar of its capital allocation strategy is an aggressive and consistent share repurchase program, which actively reduces the number of outstanding shares. In fiscal 2025 alone, the company bought back $3.1 billion of its stock. This activity significantly outweighs any new shares that might be issued as part of executive compensation.  
  • Has the business environment changed recently? Yes, the business environment has seen several significant changes. Key recent developments include the strategic realignment of its business segments to focus on high-growth areas, the announced intention to separate its Medical-Surgical Solutions segment, and a continued push into oncology and biopharma services through acquisitions. Externally, the market has been shaped by the massive revenue tailwind from GLP-1 weight-loss drugs, persistent drug shortages, ongoing pricing pressure on generic drugs, and increased regulatory scrutiny of vertical integration in the healthcare sector.  
  • Has the company made any significant acquisitions recently? Yes. As part of its strategy to expand its higher-margin service platforms, McKesson has recently been active with acquisitions. In fiscal 2025 and early fiscal 2026, the company completed or announced agreements to acquire controlling interests in PRISM Vision Holdings (an ophthalmology management services provider) and Florida Cancer Specialists’ Core Ventures, further expanding its market-leading oncology platform. It also acquired healthcare data platform Compile, Inc. in January 2024.  
  • Has the company recently changed accounting policies? The materials reviewed do not indicate any significant changes to the company’s fundamental accounting policies under U.S. GAAP. However, the company did announce a significant change to its reporting structure, which will be effective in the second quarter of fiscal 2026. This involves realigning its business into new reportable segments to provide investors with greater transparency into its strategic growth areas, like Oncology & Multispecialty services.  
  • How CapEx hungry is this business? What % of cash from operations must be spent on CapEx to sustain the business? The business is not capital expenditure (CapEx) intensive. In fiscal year 2025, McKesson generated $6.1 billion in cash from operations and spent $859 million on capital expenditures. This means that CapEx represented only about  
  • 14% of cash from operations, a relatively low figure that indicates the business generates substantial cash flow well in excess of what is needed to maintain and sustain its operations.
  • How conservative is the company’s accounting? Are they over- or under- stating earnings? The company’s accounting appears to be reasonably conservative. The most significant indicator was the decision in fiscal 2021 to take a pre-tax charge of $8.1 billion to create a reserve for its estimated liability in the national opioid litigation. Recognizing such a large liability proactively suggests a conservative approach rather than one that defers bad news. There is no indication that the company is over- or under-stating its earnings.  
  • How many options / shares is the management issuing to insiders? Is it more than 10% of net income? While the specific number of shares issued to insiders is not detailed in the provided materials, it is negligible compared to the company’s share repurchase activity. In fiscal 2025, McKesson’s net income was $3.3 billion, and it repurchased $3.1 billion worth of stock. Any new share issuance for compensation would be a very small fraction of the amount being actively retired from the market, and it would not approach 10% of net income.  
  • How much free cash flow does the business generate? How does management use this free cash flow? What is their philosophy? The business is a prolific generator of free cash flow, producing $5.2 billion in fiscal year 2025. Management’s capital allocation philosophy is disciplined and balanced, focusing on reinvesting for growth and returning capital to shareholders. Free cash flow is used for strategic acquisitions to build its oncology and biopharma platforms, significant share repurchases, and a consistently growing dividend.  
  • How profitable is this business? What is the return on capital invested? Return on equity? The business is characterized by very high revenue volume and thin profit margins. In fiscal 2025, it generated $3.3 billion in net income on $359.1 billion in revenue. Return on Equity (ROE) is not a meaningful metric because the company has negative shareholders’ equity on its balance sheet. A more useful metric is Return on Invested Capital (ROIC), which one source calculates as a very strong 60.5%. This high figure reflects the company’s efficient use of its capital base to generate earnings.  
  • How profitable is this industry? Are there a lot of competitors? What are the barriers to entry? The pharmaceutical distribution industry has low profitability, with razor-thin operating margins. There are very few competitors; the market is a consolidated oligopoly where the “Big Three”—McKesson, Cencora, and Cardinal Health—control approximately 95% to 98% of the U.S. market. Barriers to entry are exceptionally high, stemming from the immense capital required for a national distribution network, sophisticated logistics, regulatory hurdles, and deeply entrenched customer relationships.  
  • How stable are revenues? How much do they fluctuate with the economy? Revenues are highly stable and resilient. The business has demonstrated consistent top-line growth over the past five years. Demand for pharmaceuticals and medical supplies is largely non-cyclical and does not fluctuate significantly with the broader economy.  
  • Is net income diverging from cash from operations? No, in fact, cash from operations (CFO) is consistently and significantly higher than net income, which is a sign of high-quality earnings. For fiscal 2025, CFO was $6.1 billion, while net income was $3.3 billion. This positive divergence is typical for a company with large non-cash expenses like depreciation and amortization.  
  • Is the company buying back shares? Paying dividends? Yes, both are key components of its capital return strategy. The company has an aggressive share repurchase program, buying back $3.1 billion in stock in fiscal 2025. It also has a long track record of paying and growing its dividend, with the most recent 15% increase in July 2025 marking the ninth consecutive year of dividend growth.  
  • Is the stock and ADR? What are the ADR fees? McKesson’s stock, ticker symbol MCK, is a common stock listed on the New York Stock Exchange (NYSE). It is not an American Depositary Receipt (ADR).  
  • Outlook for the company’s products and services? How big will this market be? Is it growing? Shrinking? Domestic or international? The outlook is positive. The overall U.S. pharmaceutical market is large and projected to grow at a compound annual growth rate (CAGR) of 5.72% between 2025 and 2030. The fastest-growing segments are specialty drugs and biologics, which aligns directly with McKesson’s strategic focus on expanding its oncology and biopharma services. The company’s business is now primarily focused on the domestic North American market following its exit from Europe.  
  • Recent changes in the business, new markets, new production facilities, what’s changed recently? New management? The most significant recent changes are strategic and organizational. In 2025, McKesson announced a new reporting structure to better highlight its growth businesses and its intent to separate the Medical-Surgical Solutions segment into a standalone company. It has also been actively acquiring companies to expand its presence in provider services, particularly in oncology and ophthalmology. There have been no recent changes announced regarding the CEO or other top executive leadership.  
  • What are the motivations of management? Do they own a lot of stock and options? Management’s stated priorities are focused on driving sustainable growth in the core business while reallocating capital and resources to higher-growth, higher-margin areas like oncology and biopharma services. This strategy is explicitly designed to create long-term shareholder value. Executive compensation programs are linked to achieving financial objectives, which aligns management’s motivations with those of shareholders.  
  • What are the recent news on the company? The most significant recent news items from September 2025 include the announcement of a new organizational structure and the hosting of an Investor Day where the company unveiled updated, higher long-term financial targets. Other recent events include a 15% dividend increase in July 2025 and the Q1 fiscal 2026 earnings report in August 2025.  
  • What factors would cause the stock to decline? Are these factors controlled by the company or the external environment? Factors that could cause the stock to decline include:
    • External Factors: Increased government regulation on drug pricing, significant antitrust action challenging the company’s vertical integration strategy, or a prolonged deflationary environment for generic drugs could compress margins and negatively impact the stock.  
    • Internal Factors: The primary internal risk is execution risk—specifically, a failure to successfully integrate acquisitions and meet the ambitious growth targets set for the high-margin oncology and biopharma segments. A major operational failure or cybersecurity event would also pose a significant risk.  
  • What is the nature of competition? Do brand names matter? What are the customers switching costs? Competition is limited to a rational oligopoly of three dominant players. While the McKesson brand name is important for trust and reliability, the primary competitive differentiators are scale and operational efficiency. Customer switching costs are very high and represent the company’s main competitive advantage. These costs arise from deep operational integration with customers’ ordering and inventory systems and participation in joint generic drug sourcing ventures that are difficult to leave.  
  • What is the risk of a catastrophic loss on this investment? What is the chance of a total loss? The risk of a total or catastrophic loss is extremely low. McKesson is an essential part of the U.S. healthcare system’s infrastructure, and its business is protected by immense barriers to entry. A catastrophic event would likely require an unprecedented regulatory action that dismantles the industry or a complete operational collapse, both of which are highly improbable scenarios.  
  • What off B/S liabilities does the company have? The financial documents reviewed do not indicate any significant off-balance sheet liabilities. The company’s largest recent liability, related to the opioid litigation, has been quantified and is reflected in its financial statements.  
  • What is the compensation policy of directors and management? The company’s compensation policy, as overseen by the Board’s Compensation Committee, is designed to align executive pay with performance. It links compensation to achieving financial objectives and long-term strategic goals, with the stated aim of creating value for shareholders.  

Works cited

  1. 3 Stocks to Watch in the Drug Distribution Industry | Morningstar, accessed September 23, 2025, https://www.morningstar.com/stocks/investment-opportunities-drug-distribution-industry
  2. Big Pharma middlemen McKesson (NYSE: MCK), Cencora (NYSE: COR) and Cardinal Health (NYSE: CAH) draw scrutiny over push to expand into cancer care | Quantfury, accessed September 23, 2025, https://quantfury.com/market-insights/mckesson/
  3. 2024-9-26 Letter to FTC on McKesson and Cardinal Health …, accessed September 23, 2025, https://www.economicliberties.us/wp-content/uploads/2024/09/2024-9-26-Letter-to-FTC-on-McKesson-and-Cardinal-Health-Proposed-Acquisitions-FINAL.pdf
  4. McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions, accessed September 23, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2025/mckesson-reports-fiscal-2025-fourth-quarter-and-full-year-results/
  5. MCKESSON CORP SEC 10-K Report – TradingView, accessed September 23, 2025, https://www.tradingview.com/news/tradingview:372a18984ae44:0-mckesson-corp-sec-10-k-report/
  6. McKesson Corporation Highlights Strategic Growth Strategies and …, accessed September 23, 2025, https://www.pharmiweb.com/press-release/2025-09-23/mckesson-corporation-highlights-strategic-growth-strategies-and-unveils-updated-long-term-financial
  7. McKesson Announces New Organizational Structure, accessed September 23, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2025/mckesson-announces-new-organizational-structure/
  8. ANNUAL REPORT, accessed September 23, 2025, https://s24.q4cdn.com/128197368/files/doc_financials/annual/2024/756587_002_web_bmk.pdf
  9. mck-20250331 – SEC.gov, accessed September 23, 2025, https://www.sec.gov/Archives/edgar/data/927653/000092765325000036/mck-20250331.htm
  10. McKESSON CORPORATION – SEC.gov, accessed September 23, 2025, https://www.sec.gov/Archives/edgar/data/927653/000092765324000065/mck-2024xdef14a.pdf
  11. MCK McKesson Corporation Peers & Competitors – Seeking Alpha, accessed September 23, 2025, https://seekingalpha.com/symbol/MCK/peers/comparison
  12. MCKESSON CORP (Form: 10-K, Received: 05/08/2024 06:01:39) – EDGAR Online, accessed September 23, 2025, https://content.edgar-online.com/ExternalLink/EDGAR/0000927653-24-000035.html?hash=c2cb8975817a981df626bc5436316c813071f8e6f8e8f2bf9db26aa076c07964&dest=mck-20240331_htm
  13. McKesson Corporation – 10K – Annual Report – May 9, 2023, accessed September 23, 2025, https://fintel.io/doc/sec-mckesson-corp-927653-10k-2023-may-09-19486-7144
  14. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K McKESSON CORPORATION, accessed September 23, 2025, https://s24.q4cdn.com/128197368/files/doc_financials/2021/q4/MCK-Q4FY21-10-K.pdf
  15. Form 10-K – SEC.gov, accessed September 23, 2025, https://www.sec.gov/Archives/edgar/data/927653/000092765319000009/mck_10kx3312019.htm
  16. Cardinal Health, Cencora, and McKesson Expand Biosimilar Access Through Vertical Integration in Provider-Administered Drug Market – GeneOnline News, accessed September 23, 2025, https://www.geneonline.com/cardinal-health-cencora-and-mckesson-expand-biosimilar-access-through-vertical-integration-in-provider-administered-drug-market/
  17. Healthcare Distribution Market Size, Trends, Share Analysis 2025 – 2030, accessed September 23, 2025, https://www.mordorintelligence.com/industry-reports/healthcare-distribution-market
  18. National Opioid Litigation: Settlement Agreements as of January 2025 – Congress.gov, accessed September 23, 2025, https://www.congress.gov/crs-product/LSB11270
  19. McKesson Revenue 2010-2025 | MCK – Macrotrends, accessed September 23, 2025, https://macrotrends.net/stocks/charts/MCK/mckesson/revenue
  20. McKesson Net Income 2010-2025 | MCK – Macrotrends, accessed September 23, 2025, https://macrotrends.net/stocks/charts/MCK/mckesson/net-income
  21. McKesson Balance Sheet 2009-2025 | MCK – Macrotrends, accessed September 23, 2025, https://macrotrends.net/stocks/charts/MCK/mckesson/balance-sheet
  22. McKesson Cash Flow from Operating Activities 2010-2025 | MCK – Macrotrends, accessed September 23, 2025, https://macrotrends.net/stocks/charts/MCK/mckesson/cash-flow-from-operating-activities
  23. Drug Shortages: Root Causes and Recommended Solutions – McKesson, accessed September 23, 2025, https://www.mckesson.com/siteassets/documents/pharmaceutical-distribution/mckesson-drug-shortages-whitepaper/mckesson-drug-shortages-whitepaper/
  24. mck-20210331 – SEC.gov, accessed September 23, 2025, https://www.sec.gov/Archives/edgar/data/927653/000092765321000039/mck-20210331.htm
  25. McKesson Debt to Equity Ratio 2010-2025 | MCK – Macrotrends, accessed September 23, 2025, https://macrotrends.net/stocks/charts/MCK/mckesson/debt-equity-ratio
  26. McKesson Corporation Reports Fiscal 2024 First Quarter Results, accessed September 23, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2023/mckesson-corporation-reports-fiscal-2024-first-quarter-results/
  27. McKesson Corporation – Investor Relations, accessed September 23, 2025, https://investor.mckesson.com/overview/default.aspx
  28. McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance, accessed September 23, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2025/mckesson-corporation-reports-fiscal-2026-first-quarter-results/
  29. McKesson Corporation Reports Fiscal 2025 Third Quarter Results and Raises Full Year Adjusted EPS Guidance, accessed September 23, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2025/mckesson-corporation-reports-fiscal-2025-third-quarter-results/
  30. McKesson (MCK): Assessing Valuation as Business Restructuring Targets High-Growth Healthcare Segments – Simply Wall St News, accessed September 23, 2025, https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/mckesson-mck-assessing-valuation-as-business-restructuring-t
  31. Transforming Pharmaceutical Distribution Through Automation | Our Stories – McKesson, accessed September 23, 2025, https://www.mckesson.com/stories-insights/transforming-pharmaceutical-distribution-through-automation/
  32. Breaking down the impact of automation in manufacturing – MIT Science Policy Review, accessed September 23, 2025, https://sciencepolicyreview.org/wp-content/uploads/securepdfs/2023/08/MITSPR-v4-191618004018.pdf
  33. Mckesson Corp (MCK) Earnings: FY Adjusted EPS Forecast Surpasses Estimates, Expands Growth Targets Ahead of 2025 Investor Day | Smartkarma, accessed September 23, 2025, https://www.smartkarma.com/home/newswire/earnings-alerts/mckesson-corp-mck-earnings-fy-adjusted-eps-forecast-surpasses-estimates-expands-growth-targets-ahead-of-2025-investor-day/
  34. McKesson Reports Fiscal 2022 Fourth Quarter and Full-Year Results, accessed September 23, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2022/mckesson-reports-fiscal-2022-fourth-quarter-results/
  35. Pharma Supply Chain Disruptions: How Are Drug Shortages Impacting the Market? (Latest Stats) | PatentPC, accessed September 23, 2025, https://patentpc.com/blog/pharma-supply-chain-disruptions-how-are-drug-shortages-impacting-the-market-latest-stats
  36. AHA Senate Statement on Trade in Critical Supply Chains – American Hospital Association, accessed September 23, 2025, https://www.aha.org/testimony/2025-05-14-aha-senate-statement-trade-critical-supply-chains
  37. The Price of Health: Deconstructing the True Cost of Generic Drug Production, accessed September 23, 2025, https://www.drugpatentwatch.com/blog/breaking-down-the-cost-of-generic-drug-production-understanding-the-factors-influencing-affordability/
  38. Drug shortages in the United States and a value-based solution to alleviate them – PMC, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11217858/
  39. Generic drugs in the US are too cheap to be sustainable, experts say – The Guardian, accessed September 23, 2025, https://www.theguardian.com/science/2024/jan/18/us-generic-drugs-prices-causing-shortage
  40. Opioids – National Association of Attorneys General, accessed September 23, 2025, https://www.naag.org/issues/opioids/
  41. Distributors Announce Proposed Opioid Settlement Agreement – McKesson, accessed September 23, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2021/distributors-announce-proposed-opioid-settlement-agreement/
  42. How Business Owners Can Adapt to Rising Interest Rates | PNC Insights, accessed September 23, 2025, https://www.pnc.com/insights/small-business/manage-business-finances/how-business-owners-can-adapt-to-rising-interest-rates.html
  43. How Rising Interest Rates Affect Business Valuations – Brady Ware, accessed September 23, 2025, https://bradyware.com/how-rising-interest-rates-affect-business-valuations/
  44. McKesson (NYSE:MCK) Stock Valuation, Peer Comparison & Price Targets – Simply Wall St, accessed September 23, 2025, https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/valuation
  45. McKesson – Public Comps and Valuation Multiples, accessed September 23, 2025, https://multiples.vc/public-comps/mckesson-valuation-multiples
  46. CAH – Cardinal Health PE ratio, current and historical analysis, accessed September 23, 2025, https://fullratio.com/stocks/nyse-cah/pe-ratio
  47. COR – Cencora PE ratio, current and historical analysis – FullRatio, accessed September 23, 2025, https://fullratio.com/stocks/nyse-cor/pe-ratio
  48. COR Stock Price Quote | Morningstar, accessed September 23, 2025, https://www.morningstar.com/stocks/xnys/cor/quote
  49. MCK – Mckesson PE ratio, current and historical analysis – FullRatio, accessed September 23, 2025, https://fullratio.com/stocks/nyse-mck/pe-ratio
  50. McKesson Reports Fiscal 2021 Fourth-Quarter and Full-Year Results, accessed September 23, 2025, https://www.mckesson.com/siteassets/documents/about-mckesson/newsroom/earnings/mck-q4fy21-earnings/mck-q4fy21-earnings/
  51. PROXY STATEMENT, accessed September 23, 2025, https://s24.q4cdn.com/128197368/files/doc_financials/2025/ar/MCK-BMK-Proxy.pdf